Status:
COMPLETED
Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Breast Cancer
Cardiotoxicity
Eligibility:
All Genders
21+ years
Brief Summary
This is a companion study to the "Pragmatic Randomized Trial of Proton vs Photon Therapy for Patients with non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparat...
Detailed Description
The study population of the companion study will consist of newly enrolled RadComp trial participants. Patients on this ancillary will be consented prior to RadComp randomization to decrease the bias ...
Eligibility Criteria
Inclusion
- Consented to RadComp
- Willing and able to provide written consent
Exclusion
- Knowledge of randomization on RadComp prior to enrollment on companion study
- Non-diagnostic echocardiography windows as assessed on local read.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 29 2025
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04361240
Start Date
August 1 2020
End Date
May 29 2025
Last Update
July 28 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35233
2
Northwestern Medicine
Warrenville, Illinois, United States, 60555
3
Johns Hopkins
Baltimore, Maryland, United States, 21287
4
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065